Reducing the rate of venous thromboembolism in patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy
Summary
Patients with ovarian cancer are at high risk of blood clots, which can result in hospital admissions, delays in surgery and treatment, and potentially affect survival. It is estimated that over 10% of patients receiving neoadjuvant chemotherapy (chemotherapy before surgery) for ovarian cancer will have a blood clot during their treatment.
The purpose of this study is to determine if taking a low dose blood thinner (prophylactic anticoagulant) can reduce this risk, without increasing side effects of bleeding, or negatively affecting quality of life.
Eligibility
Eligible ages: 28 to 100
Inclusion criteria:
1. Adult patients over the age of 18
2. Diagnosis of advanced ovarian, fallopian tube, or primary peritoneal cancer
3. Receiving neoadjuvant chemotherapy
Participate
Additional information
Contact information
Recruitment is through identification of eligible patients at the Arthur J.E. Child Comprehensive Cancer Centre
Principal investigator:
Kristin Black
Clinical trial:
No
REB-ID:
HREBA.CC-25-0085